[go: up one dir, main page]

TN2015000235A1 - Compositions comprising vortioxetine and donepezil - Google Patents

Compositions comprising vortioxetine and donepezil

Info

Publication number
TN2015000235A1
TN2015000235A1 TNP2015000235A TN2015000235A TN2015000235A1 TN 2015000235 A1 TN2015000235 A1 TN 2015000235A1 TN P2015000235 A TNP2015000235 A TN P2015000235A TN 2015000235 A TN2015000235 A TN 2015000235A TN 2015000235 A1 TN2015000235 A1 TN 2015000235A1
Authority
TN
Tunisia
Prior art keywords
vortioxetine
donepezil
compositions
treatment
composition
Prior art date
Application number
TNP2015000235A
Other languages
English (en)
Inventor
Connie Sanchez Morillo
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of TN2015000235A1 publication Critical patent/TN2015000235A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
TNP2015000235A 2012-12-13 2015-05-27 Compositions comprising vortioxetine and donepezil TN2015000235A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261736799P 2012-12-13 2012-12-13
PCT/EP2013/076337 WO2014090929A1 (fr) 2012-12-13 2013-12-12 Compositions comprenant de la vortioxétine et du donépézil

Publications (1)

Publication Number Publication Date
TN2015000235A1 true TN2015000235A1 (en) 2016-10-03

Family

ID=49943326

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2015000235A TN2015000235A1 (en) 2012-12-13 2015-05-27 Compositions comprising vortioxetine and donepezil

Country Status (44)

Country Link
US (1) US9211288B2 (fr)
EP (1) EP2931276B1 (fr)
JP (1) JP6257641B2 (fr)
KR (1) KR102171152B1 (fr)
CN (1) CN104853755B (fr)
AP (1) AP2015008498A0 (fr)
AR (2) AR093939A1 (fr)
AU (1) AU2013357308B2 (fr)
BR (1) BR112015013675B1 (fr)
CA (1) CA2893468C (fr)
CL (1) CL2015001615A1 (fr)
CR (1) CR20150303A (fr)
CY (1) CY1120098T1 (fr)
DK (1) DK2931276T3 (fr)
DO (1) DOP2015000133A (fr)
EA (1) EA028300B1 (fr)
EC (1) ECSP15023182A (fr)
ES (1) ES2663680T3 (fr)
GE (1) GEP201706739B (fr)
GT (1) GT201500143A (fr)
HR (1) HRP20180333T1 (fr)
HU (1) HUE036280T2 (fr)
IL (1) IL239192B (fr)
LT (1) LT2931276T (fr)
MA (1) MA38253B1 (fr)
ME (1) ME03029B (fr)
MX (1) MX362886B (fr)
MY (1) MY171802A (fr)
NI (1) NI201500078A (fr)
NO (1) NO2970700T3 (fr)
NZ (1) NZ708595A (fr)
PE (1) PE20151026A1 (fr)
PH (1) PH12015501302A1 (fr)
PL (1) PL2931276T3 (fr)
PT (1) PT2931276T (fr)
RS (1) RS56949B1 (fr)
RU (1) RU2635528C2 (fr)
SG (1) SG11201504483YA (fr)
SI (1) SI2931276T1 (fr)
SM (1) SMT201800135T1 (fr)
TN (1) TN2015000235A1 (fr)
UA (1) UA114016C2 (fr)
WO (1) WO2014090929A1 (fr)
ZA (1) ZA201504274B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105218482B (zh) * 2014-06-24 2018-04-06 杭州和泽医药科技有限公司 沃替西汀氢溴酸盐β晶型的制备方法
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
CN105315184B (zh) * 2015-06-26 2017-03-29 上海医药工业研究院 一种沃替西汀的制备方法及其中间体
US10493046B2 (en) * 2015-07-17 2019-12-03 Universite Paris Descartes 5-hydroxytryptamine 1B receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
CN105534933A (zh) * 2016-01-19 2016-05-04 美吉斯制药（厦门）有限公司 一种沃替西汀口腔崩解片及其制备方法
CN109310691A (zh) 2016-07-01 2019-02-05 H.隆德贝克有限公司 用于快速开始抗抑郁作用的给药方案
JP6801129B2 (ja) * 2017-03-30 2020-12-16 ランドル リサーチ，エルエルシー うつ病の治療方法
US10398691B2 (en) 2017-03-30 2019-09-03 Rundle Research, LLC Methods of treating depression
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268871A1 (fr) 1986-10-31 1988-06-01 Sumitomo Pharmaceuticals Company, Limited Dérivés de quinoléine
IT1225462B (it) 1987-04-03 1990-11-14 Mediolanum Farmaceutici Srl Sali organici di derivati della fisostigmina
KR100195399B1 (ko) 1987-05-04 1999-06-15 보니데이비스 알쯔하이머 병 치료용 의약
EP0403713A1 (fr) 1989-06-22 1990-12-27 Merrell Dow Pharmaceuticals Inc. Inhibiteurs d'acétylcholinestérase
US4914102A (en) 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
TW200462B (fr) 1990-09-27 1993-02-21 Hoechst Roussel Pharma
US5246947A (en) 1991-09-23 1993-09-21 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
US5231093A (en) 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
ES2042384B1 (es) 1991-12-26 1994-06-01 Boehringer Ingelheim Espana Procedimiento para obtener derivados bis-piridinicos.
SE9302080D0 (sv) 1993-06-16 1993-06-16 Ab Astra New compounds
BR9708655A (pt) 1996-04-12 1999-08-03 Hoechst Marion Roussel Inc Derivados de isatina como inibidores de acetilcolinesterase e analgésicos
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
EP1491531B1 (fr) 2002-03-29 2007-12-26 Eisai R&D Management Co., Ltd. Derive de (1-indanone)-(1,2,3,6-tetrahydropyridine)
ES2314200T3 (es) * 2002-05-31 2009-03-16 H. Lundbeck A/S Una combinacion de un antagonista de nmda e inhibidores de esterasa de acetilcolina par ael tratamiento de la enfermedad de alzheimer.
US20060135403A1 (en) * 2002-12-24 2006-06-22 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
CN101460156B (zh) * 2006-05-08 2011-06-08 帝国制药株式会社 抗痴呆药的经皮吸收制剂
JP2009539850A (ja) * 2006-06-09 2009-11-19 ワイス 認知機能を増強する方法
AR061481A1 (es) * 2006-06-16 2008-08-27 Lundbeck & Co As H Compuestos con actividad combinada sobre sert, 5-ht3 y 5-ht1a
WO2009005519A1 (fr) * 2007-06-29 2009-01-08 Accera, Inc. Combinaisons de triglycérides à chaîne moyenne et d'agents thérapeutiques pour le traitement et la prévention de la maladie d'alzheimer et d'autres maladies résultant d'un métabolisme neuronal réduit
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW201033181A (en) 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Also Published As

Publication number Publication date
KR102171152B1 (ko) 2020-10-29
SMT201800135T1 (it) 2018-05-02
CA2893468C (fr) 2021-01-12
CR20150303A (es) 2016-07-07
MA38253A1 (fr) 2017-02-28
US20150297585A1 (en) 2015-10-22
CN104853755A (zh) 2015-08-19
NI201500078A (es) 2016-02-15
KR20150095681A (ko) 2015-08-21
IL239192A0 (en) 2015-07-30
AR125920A2 (es) 2023-08-23
WO2014090929A1 (fr) 2014-06-19
GT201500143A (es) 2016-01-22
HRP20180333T1 (hr) 2018-04-06
BR112015013675A2 (pt) 2017-07-11
CN104853755B (zh) 2017-08-22
AP2015008498A0 (en) 2015-05-31
UA114016C2 (xx) 2017-04-10
CL2015001615A1 (es) 2015-08-07
EA201590932A1 (ru) 2015-10-30
SI2931276T1 (en) 2018-05-31
NO2970700T3 (fr) 2018-05-26
GEP201706739B (en) 2017-09-25
LT2931276T (lt) 2018-04-10
ZA201504274B (en) 2016-11-30
CY1120098T1 (el) 2018-12-12
MY171802A (en) 2019-10-30
RU2015122256A (ru) 2017-01-16
EA028300B1 (ru) 2017-10-31
ES2663680T3 (es) 2018-04-16
CA2893468A1 (fr) 2014-06-19
RU2635528C2 (ru) 2017-11-13
AU2013357308A1 (en) 2015-06-18
PH12015501302B1 (en) 2016-02-01
DOP2015000133A (es) 2015-11-30
EP2931276A1 (fr) 2015-10-21
US9211288B2 (en) 2015-12-15
MX362886B (es) 2019-02-22
BR112015013675B1 (pt) 2022-04-26
DK2931276T3 (en) 2018-03-26
HK1212601A1 (en) 2016-06-17
AU2013357308B2 (en) 2017-08-31
PE20151026A1 (es) 2015-07-11
ME03029B (fr) 2018-10-20
AR093939A1 (es) 2015-07-01
EP2931276B1 (fr) 2018-02-21
IL239192B (en) 2019-03-31
MA38253B1 (fr) 2017-10-31
JP2016502990A (ja) 2016-02-01
SG11201504483YA (en) 2015-07-30
ECSP15023182A (es) 2015-12-31
MX2015007269A (es) 2015-08-12
HUE036280T2 (hu) 2018-06-28
PL2931276T3 (pl) 2018-06-29
PH12015501302A1 (en) 2016-02-01
NZ708595A (en) 2019-06-28
RS56949B1 (sr) 2018-05-31
JP6257641B2 (ja) 2018-01-10
PT2931276T (pt) 2018-03-19

Similar Documents

Publication Publication Date Title
IL266582A (en) Preparations and methods for the treatment of hemoglobin diseases
PH12015501302A1 (en) Compositions comprising vortioxetine and donepezil
GB201106750D0 (en) Novel compounds
TN2015000278A1 (en) Autotaxin inhibitors
IL235767A (en) Preserved pyrolidines, pharmaceuticals containing them and their uses
IL235923B (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical preparations thereof
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
IL238177A0 (en) Methods and preparations for the treatment of cancer
GB2501611B (en) Alpha-2-macroglobulin compositions and therapeutic uses
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
ZA201408056B (en) Compositions and methods for the treatment of mucositis
ZA201408055B (en) Compositions and methods for the treatment of local pain
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
ZA201408065B (en) Compositions and methods for the treatment of diabetes
GB201223374D0 (en) Personal care composition and methods of making the same
EP2902027A4 (fr) Composition de médicament pour le traitement de tumeurs et son application
GB2519004A (en) Quinone compounds and their uses for the treatment of cancer
GB201207064D0 (en) Pharmaceutical compositions comprising 15-hetre and methods of using the same
PT2812351T (pt) Composição farmacêutica para o tratamento de esclerose múltipla
AU2012902982A0 (en) Compositions and methods for the treatment of tuberculosis